Journal Logo

You can read the full text of this article if you:

Ovid Member Institutional Access

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers

A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22)

Karoui, M. MD, PhD; Rullier, A. MD; Piessen, G. MD, PhD; Legoux, J. L. MD§; Barbier, E. MD; De Chaisemartin, C. MD||; Lecaille, C. MD∗∗; Bouche, O. MD, PhD††; Ammarguellat, H. MD‡‡; Brunetti, F. MD§§; Prudhomme, M. MD, PhD¶¶; Regimbeau, J. M. MD, PhD||||; Glehen, O. MD, PhD∗∗∗; Lievre, A. MD, PhD†††; Portier, G. MD, PhD‡‡‡; Hartwig, J. MD§§§; Goujon, G. MD¶¶¶; Romain, B. MD, PhD||||||; Lepage, C. MD, PhD∗∗∗∗; Taieb, J. MD, PhD††††; for PRODIGE 22 investigators/collaborators

Author Information
doi: 10.1097/SLA.0000000000003454
  • Buy
  • SDC


Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.